Pharma BD Deal Intelligence
Vertex Pharmaceuticals' up-to-$1B acquisition of Exonics Therapeutics to build out a Duchenne muscular dystrophy pipeline—a bet on gene-editing therapy for a devastating rare disease, though no clinical or commercial milestones have yet emerged to validate the price tag.
Vertex agrees to acquire Exonics Therapeutics for $245M upfront plus up to $1B in milestones for gene editing therapies in muscular dystrophy
Vertex grows gene editing presence acquiring Exonics and expanding CRISPR Therapeutics collaboration for Duchenne muscular dystrophy
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Vertex acquired Exonics for up to $1B for Duchenne muscular dystrophy treatments.
400 US cases/yr · $2.1B North America DMD Treatment (2024)
Duchenne muscular dystrophy affects ~16,000+ Americans, caused by dystrophin gene mutations. It is the most common childhood muscular dystrophy. Vertex acquired Exonics for CRISPR-based gene editing to restore dystrophin expression, a fundamentally different approach from gene replacement.
DMD treatments: exon-skipping ASOs (Sarepta: eteplirsen, casimersen, golodirsen), gene therapy (Elevidys, Sarepta/Roche, $1B+ in 2024), steroids. Vertex's CRISPR approach (VX-981) aims for permanent genomic correction rather than transient gene expression. The approach is earlier stage but potentially more durable than AAV gene therapy.
DM1 has no approved disease-modifying therapy; the competitive landscape is entirely pipeline-stage, split across three MOA classes targeting the CUG-expansion RNA toxicity of DMPK. Antibody-oligonucleotide conjugates (AOC): Avidity Biosciences' del-desiran (AOC 1001) is the furthest-advanced, a TfR1-antibody-siRNA conjugate in the Phase 3 HARBOR trial after positive MARINA readouts showing splicing correction and video hand-opening improvement. Dyne Therapeutics' DYNE-101 (FORCE platform TfR1-PMO) entered Phase 1/2 ACHIEVE and reported functional improvements in 2024. Oral small-molecule splicing modulators: Pepgen's PGN-EDODM1 (Phase 1 FREEDOM/FREEDOM2) uses enhanced delivery oligonucleotide chemistry for DMPK knockdown. Gene editing: Vertex's acquired Exonics program (CRISPR-based DMPK targeting), plus Entrada Therapeutics' ENTR-701 (Endosomal Escape Vehicle conjugate) in early clinical development. Sarepta also disclosed preclinical DM1 programs. Commercial threat sizing: Avidity leads by ~2 years clinical-timeline and has established TfR1-conjugate validation. Vertex's CRISPR approach competes on durability (potentially one-time dose versus chronic Q-weekly/monthly conjugate dosing) but faces longer regulatory path, CMC complexity for muscle-wide delivery, and safety scrutiny on off-target editing. Commercial wedge for Vertex is curative positioning; near-term share belongs to AOC/PMO conjugates.
Vertex completed up to $1B acquisition of Exonics Therapeutics, gaining gene editing platform for Duchenne muscular dystrophy and myotonic dystrophy.
Vertex advanced Exonics-derived CRISPR gene editing programs for DMD through preclinical/early clinical development to restore dystrophin.
Exonics gene editing for DMD still early. $1B is strategic option on potentially transformative approach but years from commercial impact.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated / Exonics Therapeutics (this deal) | 2005 | $1.0B | 54 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Vertex Pharmaceuticals Incorporated / Semma Therapeutics Inc. | 2019 | $950M | 86 |
| Vertex Pharmaceuticals Incorporated / Concert Pharmaceuticals, Inc. | 2017 | $250M | 85 |
| Vertex Pharmaceuticals Incorporated / CRISPR Therapeutics AG | 2015 | $2.6B | 85 |
| Vertex Pharmaceuticals Incorporated / Alpine Immune Sciences | 2024 | $4.9B | 78 |
| Vertex Pharmaceuticals Incorporated / Crinetics Pharmaceuticals, Inc. | 2026 | $10.0B | 68 |
← Browse all deals · How we score deals
More: 2005 deals · Vertex Pharmaceuticals Incorporated deals · Rare Disease deals